Literature DB >> 31316136

Viral vector: potential therapeutic for glioblastoma multiforme.

Ceera Manikandan1, Akshita Kaushik1, Dwaipayan Sen2.   

Abstract

Glioblastoma multiforme is a highly malignant primary brain tumour found in adults and is highlighted as the most devastating among all the other grades of glioma. Well-established standard treatment methods, such as chemotherapy, radiation and surgery, have resulted in modest improvement in the survival of patients. Hence, the arduous search for novel treatments backed by advancements in molecular biology still persists. Glioblastoma has many distinctive characteristics, which makes it a potential candidate for gene therapy. Gene therapy involves the delivery of genetic material of therapeutic use into tumour cells, which produces a specific antitumour response. Moreover, viruses stimulate a vigorous cytotoxic effect, they are easily modifiable and the inherent property of horizontal transfer of genetic material makes them valuable tools for genetic engineering. In this review, we have enlisted the various viral vectors employed in gene therapy for glioblastoma.

Entities:  

Mesh:

Year:  2019        PMID: 31316136     DOI: 10.1038/s41417-019-0124-8

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  60 in total

Review 1.  Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment.

Authors:  Patrick Y Wen; David A Reardon
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

2.  CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010.

Authors:  Quinn T Ostrom; Haley Gittleman; Paul Farah; Annie Ondracek; Yanwen Chen; Yingli Wolinsky; Nancy E Stroup; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2013-11       Impact factor: 12.300

3.  Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma.

Authors:  Wenting Wu; Kathleen R Lamborn; Jan C Buckner; Paul J Novotny; Susan M Chang; Judith R O'Fallon; Kurt A Jaeckle; Michael D Prados
Journal:  Neuro Oncol       Date:  2009-12-21       Impact factor: 12.300

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  Complement activation in Glioblastoma multiforme pathophysiology: evidence from serum levels and presence of complement activation products in tumor tissue.

Authors:  T A M Bouwens; L A Trouw; R Veerhuis; C M F Dirven; M L M Lamfers; H Al-Khawaja
Journal:  J Neuroimmunol       Date:  2014-11-18       Impact factor: 3.478

6.  One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned?

Authors:  Dieter Henrik Heiland; Gerrit Haaker; Ralf Watzlawick; Daniel Delev; Waseem Masalha; Pamela Franco; Marcia Machein; Ori Staszewski; Oliver Oelhke; Nils Henrik Nicolay; Oliver Schnell
Journal:  J Neurooncol       Date:  2018-08-03       Impact factor: 4.130

7.  Psychometric- and quality-of-life assessment in long-term glioblastoma survivors.

Authors:  Manuela Schmidinger; Leo Linzmayer; Alexander Becherer; Barbara Fazeny-Doemer; Negar Fakhrai; Daniela Prayer; Monika Killer; Karl Ungersboeck; Karin Dieckmann; Christine Marosi
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

Review 8.  Management of glioblastoma in elderly patients.

Authors:  Jacob S Young; Steven J Chmura; Derek A Wainwright; Bakhtiar Yamini; Katherine B Peters; Rimas V Lukas
Journal:  J Neurol Sci       Date:  2017-08-01       Impact factor: 3.181

9.  Strategies in gene therapy for glioblastoma.

Authors:  Aneta Kwiatkowska; Mohan S Nandhu; Prajna Behera; E Antonio Chiocca; Mariano S Viapiano
Journal:  Cancers (Basel)       Date:  2013-10-23       Impact factor: 6.639

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  10 in total

Review 1.  Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies.

Authors:  Johan Karlsson; Kathryn M Luly; Stephany Y Tzeng; Jordan J Green
Journal:  Adv Drug Deliv Rev       Date:  2021-10-27       Impact factor: 17.873

Review 2.  Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies.

Authors:  Hannah E Olsen; Geoffrey M Lynn; Pablo A Valdes; Christian D Cerecedo Lopez; Andrew S Ishizuka; Omar Arnaout; W Linda Bi; Pier Paolo Peruzzi; E Antonio Chiocca; Gregory K Friedman; Joshua D Bernstock
Journal:  Neurooncol Adv       Date:  2021-02-11

Review 3.  Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas.

Authors:  Shalini Sundramurthi Chelliah; Ervin Ashley Lourdes Paul; Muhamad Noor Alfarizal Kamarudin; Ishwar Parhar
Journal:  Molecules       Date:  2021-02-22       Impact factor: 4.411

Review 4.  Viral Gene Therapy for Glioblastoma Multiforme: A Promising Hope for the Current Dilemma.

Authors:  Junsheng Li; Wen Wang; Jia Wang; Yong Cao; Shuo Wang; Jizong Zhao
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

5.  Anticancer Activities of 9-chloro-6-(piperazin-1-yl)-11H-indeno[1,2-c] quinolin-11-one (SJ10) in Glioblastoma Multiforme (GBM) Chemoradioresistant Cell Cycle-Related Oncogenic Signatures.

Authors:  Ntlotlang Mokgautsi; Yu-Cheng Kuo; Sung-Ling Tang; Feng-Cheng Liu; Shiang-Jiun Chen; Alexander T H Wu; Hsu-Shan Huang
Journal:  Cancers (Basel)       Date:  2022-01-05       Impact factor: 6.639

6.  Case Report: H3K27M-Mutant Glioblastoma Simultaneously Present in the Brain and Long-Segment Spinal Cord Accompanied by Acute Pulmonary Embolism.

Authors:  Buajieerguli Maimaiti; Salamaitiguli Mijiti; Ting Jiang; Yinyin Xie; Weixuan Zhao; Yu Cheng; Hongmei Meng
Journal:  Front Oncol       Date:  2022-02-08       Impact factor: 6.244

7.  UPF1/circRPPH1/ATF3 feedback loop promotes the malignant phenotype and stemness of GSCs.

Authors:  Jinkun Xu; Guoqing Zhang; Jinpeng Hu; Hao Li; Junshuang Zhao; Shengliang Zong; Zhengting Guo; Yang Jiang; Zhitao Jing
Journal:  Cell Death Dis       Date:  2022-07-23       Impact factor: 9.685

Review 8.  Overcoming the blood-brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches.

Authors:  Ksenia Mitusova; Oleksii O Peltek; Timofey E Karpov; Albert R Muslimov; Mikhail V Zyuzin; Alexander S Timin
Journal:  J Nanobiotechnology       Date:  2022-09-15       Impact factor: 9.429

Review 9.  Effects of oncolytic viruses and viral vectors on immunity in glioblastoma.

Authors:  Penghao Liu; Yaning Wang; Wenbin Ma; Yu Wang; Yuekun Wang; Ziren Kong; Wanqi Chen; Jiatong Li; Wenlin Chen; Yuanren Tong
Journal:  Gene Ther       Date:  2020-11-15       Impact factor: 5.250

Review 10.  Oncolytic Viruses for Malignant Glioma: On the Verge of Success?

Authors:  Yogesh R Suryawanshi; Autumn J Schulze
Journal:  Viruses       Date:  2021-07-02       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.